ONCAlert | Upfront Therapy for mRCC

Outcomes in Progressive Large B-Cell Lymphomas Following CD19-Specific CAR T Cells

Victor Chow, MD
Published Online: 1:07 AM, Sun December 2, 2018

Victor Chow, MD, senior hematology-oncology fellow, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses a retrospective study assessing outcomes of patients with large B-cell lymphomas and progressive disease following CD19-Specific CAR T-cell therapy during the 2018 ASH Annual Meeting.

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.